Overview

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of single agent pazopanib in subjects with unresectable or metastatic liposarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Vector Oncology
Collaborator:
Novartis